University of California San Francisco
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of California San Francisco
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.
A new academic study presented at ESMO has provided the first Phase III data for tumor-infiltrating lymphocytes as a potential new therapeutic class, while industry leader Iovance looks set to have early-stage data for its TIL accepted by the US FDA.
Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.
The partners reported initial data at ASH for their BCMA-targeting CAR-T therapy in second-line multiple myeloma that appear consistent with longer-term results and ahead of their main competitor, Bristol’s Abecma.
- Academic and Research Institutions
- Other Names / Subsidiaries
- UC San Francisco